secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043487
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025
--------------------------------------------------------------------------------

- FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.
- BLA submission for accelerated approval targeted by year-end 2025; global Phase 3 study to initiate mid-2025.
- Net loss of $28.8M in Q4 2024 ($0.45/share) vs. $13.0M ($0.30/share) in Q4 2023; R&D expenses rose to $26.7M.
- Cash and equivalents $183.5M as of Dec 31, 2024; projected runway into Q2 2026.
- OLE study amended to include premedication after anaphylaxis deemed adverse drug reaction; 50 mg data expected Sept 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/0000950170-25-043487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017025043487/lrmr-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer